glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Cod is popular as a food with a mild flavour and a dense, flaky white flesh. Cod livers are processed to make cod liver oil, an important source of vitamin A, vitamin D, vitamin E and omega-3 fatty acids (EPA and DHA).
Cited half-life: the median age of the articles that were cited in Journal Citation Reports each year. For example, if a journal's half-life in 2005 is 5, that means the citations from 2001 to 2005 are half of all the citations from that journal in 2005, and the other half of the citations precede 2001. Aggregate impact factor for a subject category: it is calculated taking into account the number of citations to all journals in the subject category and the number of articles from all the journals in the subject category. Immediacy index: the number of citations the articles in a journal receive in a given year divided by the number of articles published. Journal citation indicator (JCI): a JIF that adjusts for scientific field; it is similar to Source Normalized Impact per Paper, calculated based on the Scopus database. JCI is available for all journals in the Web of Science Core Collection (WoS CC)—including the AHCI, ESCI, BCI, CPCI—while JIF is only available for the SCIE and SSCI; however, starting in June 2023, JIF will also be issued for all journals in the WoS CC. JIF quartile ranking: a rank based on the four quartiles within a given subject or topic category. JIF percentile ranking: a percentile rank computed for a particular subject category. A given journal may attain a different quartile or percentile in different categories. As with the impact factor, there are some nuances to this: for example, Clarivate excludes certain article types (such as news items, correspondence, and errata) from the denominator.
The stomach is a major organ of the gastrointestinal tract and digestive system. It is a consistently J-shaped organ joined to the esophagus at its upper end and to the duodenum at its lower end. Gastric acid (informally gastric juice), produced in the stomach plays a vital role in the digestive process, and mainly contains hydrochloric acid and sodium chloride. A peptide hormone, gastrin, produced by G cells in the gastric glands, stimulates the production of gastric juice which activates the digestive enzymes. Pepsinogen is a precursor enzyme (zymogen) produced by the gastric chief cells, and gastric acid activates this to the enzyme pepsin which begins the digestion of proteins. As these two chemicals would damage the stomach wall, mucus is secreted by innumerable gastric glands in the stomach, to provide a slimy protective layer against the damaging effects of the chemicals on the inner layers of the stomach. At the same time that protein is being digested, mechanical churning occurs through the action of peristalsis, waves of muscular contractions that move along the stomach wall. This allows the mass of food to further mix with the digestive enzymes. Gastric lipase secreted by the chief cells in the fundic glands in the gastric mucosa of the stomach, is an acidic lipase, in contrast with the alkaline pancreatic lipase. This breaks down fats to some degree though is not as efficient as the pancreatic lipase.
== Early life and education == Otto Hahn was born in Frankfurt am Main on 8 March 1879, the youngest son of Heinrich Hahn, a prosperous glazier and founder of the Glasbau Hahn company, and Charlotte Hahn (née Giese). He had an older half-brother Karl, his mother's son from her previous marriage, and two older brothers, Heiner and Julius. The family lived above his father's workshop. The younger three boys were educated at the Klinger Oberrealschule in Frankfurt. At the age of 15, Otto began to take a special interest in chemistry, and carried out simple experiments in the laundry room of the family home. His father wanted him to study architecture, as he had built or acquired several residential and business properties, but Otto persuaded him that his ambition was to become an industrial chemist. In 1897, after passing his Abitur, Hahn began to study chemistry at Marburg University. His subsidiary subjects were mathematics, physics, mineralogy and philosophy. Hahn joined the Students' Association of Natural Sciences and Medicine, a student fraternity and a forerunner of today's Landsmannschaft Nibelungi (Coburger Convent der akademischen Landsmannschaften und Turnerschaften). He spent his third and fourth semesters at the Ludwig-Maximilians-Universität München, studying organic chemistry under Adolf von Baeyer, physical chemistry under Wilhelm Muthmann, and inorganic chemistry under Karl Andreas Hofmann. In 1901, Hahn received his doctorate at Marburg University for a dissertation entitled "On Bromine Derivates of Isoeugenol", a topic in classical organic chemistry.
=== Tissue type === Cutaneous flaps contain the full thickness of the skin, fat, and superficial fascia and are used to fill small defects. These are typically supplied by a random blood supply. Examples include Z-plasty, deep inferior epigastric perforator (DIEP) flaps, and V-Y advancement flaps. Fasciocutaneous flaps contain subcutaneous tissue and deep fascia, resulting in a more robust blood supply and ability to fill a larger defect. The Cormack and Lamberty classification is used for the vascular supply of fasciocutaneous flaps. Examples include emporoparietal and anterolateral thigh fasciocutaneous flaps, lateral fasciocutaneous flaps and posterior fasciocutaneous flaps.
Sources: en.wikipedia.org
=== Pharmacokinetics === Aceclidine, when administered ophthalmically, is absorbed primarily through the conjunctival and corneal tissues. Its onset of action is rapid due to efficient local absorption. Systemically, aceclidine undergoes limited metabolism, as its primary site of effect is the eye, thereby minimizing significant systemic exposure. Distribution following ocular administration is predominantly localized, with low risk of systemic accumulation. Excretion details are not extensively characterized, but, like other topical miotic agents, aceclidine is presumed to have minimal systemic bioavailability and is likely eliminated primarily via the local ocular route and normal metabolic pathways.
== Sources cited == Emsley, John (2001). "Uranium". Nature's Building Blocks: An A to Z Guide to the Elements. Oxford, England: Oxford University Press. pp. 476–482. ISBN 978-0-19-850340-8. Seaborg, Glenn T. (1968). "Uranium". The Encyclopedia of the Chemical Elements. Skokie, Illinois: Reinhold Book Corporation. pp. 773–786. LCCN 68029938. Groves, Leslie R. (1962). Now It Can Be Told: The Story of the Manhattan Project. New York: Harper and Company. ISBN 0-306-80189-2. {{cite book}}: ISBN / Date incompatibility (help)
==== Cell-based platform ==== The immune system plays an important role in cancer and can be harnessed to attack cancer cells. Cell-based therapies focus on immunotherapies, mostly by engineering T cells. T cell receptors were engineered and 'trained' to detect cancer epitopes. Chimeric antigen receptors (CARs) are composed of a fragment of an antibody fused to intracellular T cell signaling domains that can activate and trigger proliferation of the cell. Multiple second generation CAR-based therapies have been approved by FDA. Gene switches were designed to enhance safety of the treatment. Kill switches were developed to terminate the therapy should the patient show severe side effects. Mechanisms can more finely control the system and stop and reactivate it. Since the number of T-cells are important for therapy persistence and severity, growth of T-cells is also controlled to dial the effectiveness and safety of therapeutics. Although several mechanisms can improve safety and control, limitations include the difficulty of inducing large DNA circuits into the cells and risks associated with introducing foreign components, especially proteins, into cells.
Norbert Elias; (1897-1990) sociologist especially famous for theory of civilising/decivilising processes; was deeply involved in the German Zionist movement, and acted as one of the leading intellectuals within the German-Jewish youth movement "Blau-Weiss" (Blue-White). Elias' most famous work is The Civilizing Process Samantha Ellis is an Iraqi Jewish British playwright and writer best known for her books How to be a Heroine, Chopping Onions on My Heart, and her play How to Date a Feminist. Richard Ellmann literary scholar and biographer Aaron Esterson (23 September 1923 – 15 April 1999) prolific author and psychiatrist who was one of the founders of the Philadelphia Association along with R. D. Laing, with whom he wrote Sanity, Madness, and the Family. He wrote four other scholarly texts on psychiatry and existentialism as well as countless academic papers and monographs. Hans Eysenck (4 March 1916 – 4 September 1997); author of over fifty books and numerous academic papers; of German Jewish maternal lineage; psychologist best remembered for his work on intelligence and personality, although he worked on other issues in psychology. At the time of his death, Eysenck was the most frequently cited living psychologist in the peer-reviewed scientific journal literature. Henry Ezriel (c1910-1985) was a Kleinian analyst and author who pioneered group analysis at the Tavistock Clinic; best known as the originator of one of the Malan triangles; worked alongside W. R. Bion as consultant psychiatrist to the Tavistock.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.